Oramed to Join MSCI USA Small Cap Index

Rhea-AI Summary

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) announced its common stock will be added to the MSCI USA Small Cap Index effective November 30, 2021. This milestone follows the earlier inclusion in the Russell 2000 and Russell 3000 Indexes. The MSCI USA Small Cap Index encompasses 1,851 constituents and represents about 14% of the U.S. equity market's free float-adjusted market cap. CEO Nadav Kidron expressed optimism regarding this inclusion, noting its potential to broaden the company's shareholder base.

Positive

• Inclusion in the MSCI USA Small Cap Index may enhance visibility and attractiveness to investors.
• Previously added to the Russell 2000 and Russell 3000 Indexes, indicating broader market recognition.

Negative

• None.

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its common stock will be added to the MSCI USA Small Cap Index effective Tuesday, November 30th at the close of market. The MSCI USA Small Cap Index is designed to measure the performance of the small cap segment of the U.S. equity market. With 1,851 constituents, the index represents approximately 14% of the free float-adjusted market capitalization in the U.S. Key exposures of risk and return in the index include small capitalization, value, and momentum, with 14% of the index in healthcare.  

"We welcome our inclusion in the MSCI USA Small Cap Index. Earlier this year, our stock was added to the Russell 2000®️ and Russell 3000®️ Indexes. We are pleased that inclusion of our stock in a growing number of indexes can expand our shareholder base," said Oramed Chief Executive Officer, Nadav Kidron.

About MSCI

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, MSCI powers better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901). For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential to expand Oramed's shareholder base or the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact

Josh Hexter
+1-844-9-ORAMED
josh@oramed.com

View original content:https://www.prnewswire.com/news-releases/oramed-to-join-msci-usa-small-cap-index-301431482.html

SOURCE Oramed Pharmaceuticals Inc.

FAQ

What is the significance of Oramed being added to the MSCI USA Small Cap Index?

The addition to the MSCI USA Small Cap Index can increase visibility among investors, potentially leading to a broader shareholder base.

When will Oramed be included in the MSCI USA Small Cap Index?

Oramed's common stock will be added to the MSCI USA Small Cap Index effective November 30, 2021.

Has Oramed been added to any other indices?

Yes, earlier in 2021, Oramed was also included in the Russell 2000 and Russell 3000 Indexes.

What does the MSCI USA Small Cap Index represent?

The MSCI USA Small Cap Index is designed to measure the performance of the small cap segment of the U.S. equity market, comprising 1,851 constituents.

What percentage of the MSCI USA Small Cap Index is in healthcare?

Approximately 14% of the MSCI USA Small Cap Index constituents are in the healthcare sector.